微信公众号
证券之星APP
| 报告期 | 销售毛利率 | 同比 | 环比 | 行业排名 | 行业均值 | 行业龙头股 | 龙头股该指标值 | 查看 |
|---|---|---|---|---|---|---|---|---|
| 2026-09-30 | 49.71% | 3.13% | 0.08% | 77/159 | 50.44% | 迪哲医药 | 99.22% | 行业排名> |
| 2026-06-30 | 49.67% | 3.22% | -0.06% | 76/159 | 48.66% | 海创药业 | 97.34% | 行业排名> |
| 2026-03-31 | 49.7% | 4.04% | -0.74% | 75/159 | 50.28% | 海创药业 | 99.82% | 行业排名> |
| 2025-12-31 | 50.07% | 4.38% | 3.88% | 76/159 | 50.37% | 海创药业 | 98.62% | 行业排名> |
| 2025-09-30 | 48.2% | -0.81% | 0.16% | 77/159 | -2.13% | 海创药业 | 99.57% | 行业排名> |
| 2025-06-30 | 48.12% | -1.52% | 0.74% | 79/159 | 15.05% | 海创药业 | 99.52% | 行业排名> |
| 2025-03-31 | 47.77% | -4.48% | -0.43% | 73/159 | 31.79% | 艾力斯 | 96.74% | 行业排名> |
| 2024-12-31 | 47.97% | 0.29% | -1.28% | 82/159 | 51.61% | 首药控股 | 98.96% | 行业排名> |
| 2024-09-30 | 48.6% | -0.01% | -0.55% | 81/159 | 22.43% | 迪哲医药 | 97.73% | 行业排名> |
| 2024-06-30 | 48.87% | -2.26% | -2.29% | 80/159 | 32.96% | 百利天恒 | 97.99% | 行业排名> |
| 2024-03-31 | 50.01% | -2.5% | 4.54% | 76/159 | 51.47% | 百利天恒 | 98.92% | 行业排名> |
| 2023-12-31 | 47.84% | 1.17% | -1.57% | 84/159 | 51.31% | 迈威生物 | 98.93% | 行业排名> |
| 2023-09-30 | 48.6% | 4.48% | -2.79% | 82/159 | 32.31% | 迈威生物 | 99.59% | 行业排名> |
| 2023-06-30 | 50% | 9.25% | -2.53% | 78/159 | 38.22% | 迈威生物 | 99.8% | 行业排名> |
| 2023-03-31 | 51.29% | 17.77% | 8.48% | 72/159 | 52.66% | 迈威生物 | 99.46% | 行业排名> |
| 2022-12-31 | 47.28% | -1.79% | 1.65% | 88/159 | 53.51% | 迈威生物 | 99.75% | 行业排名> |
| 2022-09-30 | 46.52% | -6.19% | 1.65% | 84/159 | 5.67% | 迈威生物 | 99.67% | 行业排名> |
| 2022-06-30 | 45.76% | -10.79% | 5.08% | 85/159 | 20.91% | 迈威生物 | 99.44% | 行业排名> |
| 2022-03-31 | 43.55% | -15.89% | -9.53% | 87/159 | 54.06% | 迈威生物 | 98.57% | 行业排名> |
| 2021-12-31 | 48.14% | -11.96% | -2.91% | 86/159 | 54.9% | 首药控股 | 99.93% | 行业排名> |
| 2021-09-30 | 49.59% | -11.24% | -3.34% | 75/159 | 46.49% | 艾力斯 | 99.41% | 行业排名> |
| 2021-06-30 | 51.3% | -7.89% | -0.94% | 76/159 | 46.97% | 艾力斯 | 98.7% | 行业排名> |
| 2021-03-31 | 51.78% | -6.07% | -5.31% | 68/159 | 53.79% | 艾力斯 | 99.4% | 行业排名> |
| 2020-12-31 | 54.69% | -8.27% | -2.12% | 71/159 | -147.51% | 首药控股 | 99.94% | 行业排名> |
| 2020-09-30 | 55.87% | -6.55% | 0.32% | 59/159 | 56.06% | 泽璟制药 | 99.96% | 行业排名> |
| 2020-06-30 | 55.69% | -7.94% | 1.02% | 61/159 | 53.85% | 微芯生物 | 95.14% | 行业排名> |
| 2020-03-31 | 55.13% | -6.76% | -7.53% | 52/159 | 54.83% | 多瑞医药 | 95.59% | 行业排名> |
| 2019-12-31 | 59.62% | 2.08% | -0.28% | 60/159 | -1232.76% | 微芯生物 | 95.81% | 行业排名> |
| 2019-09-30 | 59.79% | 2.6% | -1.17% | 47/159 | 54.86% | 微芯生物 | 96.09% | 行业排名> |
| 2019-06-30 | 60.49% | 3.77% | 2.32% | 45/159 | 54.88% | 微芯生物 | 96.11% | 行业排名> |
| 2019-03-31 | 59.12% | 2.66% | 1.23% | 43/159 | 50.75% | 微芯生物 | 95.5% | 行业排名> |
| 2018-12-31 | 58.4% | -0.92% | 0.22% | 58/159 | -210.26% | 微芯生物 | 96.27% | 行业排名> |
| 2018-09-30 | 58.27% | -0.21% | -0.04% | 44/159 | 53.75% | 贝达药业 | 95.47% | 行业排名> |
| 2018-06-30 | 58.29% | 1.85% | 1.22% | 42/159 | 53.16% | 贝达药业 | 95.51% | 行业排名> |
| 2018-03-31 | 57.59% | 4.08% | -2.29% | 43/159 | 53.78% | 贝达药业 | 95.54% | 行业排名> |
| 2017-12-31 | 58.95% | 9.01% | 0.94% | 43/159 | 52.25% | 贝达药业 | 95.74% | 行业排名> |
| 2017-09-30 | 58.39% | 8.55% | 2.02% | 31/159 | 48.76% | 退市金泰 | 96.19% | 行业排名> |
| 2017-06-30 | 57.24% | 7.07% | 3.43% | 32/159 | 47.61% | 贝达药业 | 95.81% | 行业排名> |
| 2017-03-31 | 55.34% | 7.16% | 2.34% | 30/159 | 46.62% | 退市金泰 | 95.93% | 行业排名> |
| 2016-12-31 | 54.07% | 8.21% | 0.52% | 39/159 | 48.17% | 贝达药业 | 95.58% | 行业排名> |
| 2016-09-30 | 53.8% | 6.24% | 0.63% | 26/159 | 45.83% | 贝达药业 | 95.89% | 行业排名> |
| 2016-06-30 | 53.46% | 5.8% | 3.53% | 30/159 | 45.93% | 微芯生物 | 97.46% | 行业排名> |
| 2016-03-31 | 51.64% | 4.72% | 3.34% | 25/159 | 43.86% | 贝达药业 | 97.01% | 行业排名> |